Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

[1]  S. Ito,et al.  Expression of type I and type III collagens during the course of dimethylnitrosamine-induced hepatic fibrosis in rats. , 2008, Liver.

[2]  Yoshiyuki Suzuki,et al.  Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b , 2007, Journal of medical virology.

[3]  Yoshiyuki Suzuki,et al.  Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  Sheng-Nan Lu,et al.  Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[5]  R. Levine,et al.  Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[7]  H. Goto,et al.  Treatment of Chronic Hepatitis C with Interferon Alone or Combined with Ribavirin in Japan , 2005, Intervirology.

[8]  M. Yuen,et al.  Response to Combined Interferon and Ribavirin Is Better in Patients Infected with Hepatitis C Virus Genotype 6 than Genotype 1 in Hong Kong , 2005, Intervirology.

[9]  J. Izopet,et al.  Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection , 2005, Journal of medical virology.

[10]  V. Paradis,et al.  Progression of liver fibrosis in women infected with hepatitis C: Long‐term benefit of estrogen exposure , 2004, Hepatology.

[11]  Yoshiyuki Suzuki,et al.  Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C , 2004, Journal of Gastroenterology.

[12]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[13]  W. Kremers,et al.  Osteopenia and osteoporosis in patients with end‐stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  M. Yuen,et al.  Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. , 2003, The Journal of infectious diseases.

[15]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[16]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[17]  P. Gow,et al.  Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C , 2002, Gut.

[18]  C. Rigamonti,et al.  Chronic hepatitis C is mild in menstruating women , 2000, Journal of gastroenterology and hepatology.

[19]  Trépo.  Genotype and viral load as prognostic indicators in the treatment of hepatitis C , 2000, Journal of viral hepatitis.

[20]  F. Berr,et al.  Low frequency of cirrhosis in a hepatitis C (genotype 1b) single‐source outbreak in germany: A 20‐year multicenter study , 2000, Hepatology.

[21]  A. Alberti,et al.  Natural history of hepatitis C. , 1999, Journal of hepatology.

[22]  J. Hoofnagle,et al.  Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C , 2000, Annals of Internal Medicine.

[23]  J. Saunders,et al.  Hepatitis C in injecting drug‐using women during and after pregnancy , 2000, Journal of gastroenterology and hepatology.

[24]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[25]  J. Hess,et al.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. , 1999, Clinical pediatrics.

[26]  E. Lawlor,et al.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. , 1999, The New England journal of medicine.

[27]  J Cohen,et al.  The Scientific Challenge of Hepatitis C , 1999, Science.

[28]  E. Kenny‐Walsh.  Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. , 1999, The New England journal of medicine.

[29]  I. Shimizu,et al.  Suppressive effects of estradiol on dimethylnitrosamine‐induced fibrosis of the liver in rats , 1999, Hepatology.

[30]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[31]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[32]  G G Klee,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable Estroge , 2022 .

[33]  S. Kashiwagi,et al.  Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. , 1998, Archives of internal medicine.

[34]  L. Seeff.  Natural history of hepatitis C , 1997, Clinics in liver disease.

[35]  M. Picot,et al.  Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[36]  J. Castilla,et al.  Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. , 1997, The American journal of gastroenterology.

[37]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[38]  V. Paradis,et al.  Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. , 1995, Gastroenterology.

[39]  K. Chayama,et al.  Factors predictive of response to interferon‐α therapy in hepatitis C virus infection , 1994, Hepatology.

[40]  G. Rossini,et al.  Characterization of estrogen receptor from human liver. , 1989, Gastroenterology.

[41]  H J Alter,et al.  Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term Outcome , 2000, Seminars in liver disease.

[42]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[43]  K. Chayama,et al.  Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. , 1994, Hepatology.